Imfinzi plus chemotherapy tripled patient survival at three years in the CASPIAN phase III trial in extensive-stage small cell lung cancer – AstraZeneca

Updated results from the CASPIAN Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit at three years for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting. These data, which show the longest survival update ever […]

Making CAR-T therapy most effective in leukaemia patients

Too many “exhausted” T cells left in the wake of aggressive chemotherapy regimens for patients with advanced chronic lymphocytic leukaemia (CLL) make it more challenging for chimeric antigen receptor (CAR) T cell therapy to do its job. Now, a new study from researchers at the University of Pennsylvania shows how to overcome this type of resistance and reinvigorate these T […]